C-9NYQMorphoceuticals Inc
bioelectrome, multi-omics, AI
repairingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-9NYQ
C-9NYQC-9NYQbioelectrome, multi-omics, AI
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Morphoceuticals Inc bioelectrome, multi-omics, AI
Morphoceuticals describes itself as a TechBio company building the first atlas of the bioelectrome. The company uses multi-omics, bioelectric profiling and AI to potentially switch on dormant systems controlling tissue repair and organ regeneration. Its stated focus includes manipulating bioelectric patterns for traumatic injuries, degenerative diseases, and organ failure.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
Morphoceuticals Inc — Early mechanism · Lower middle. Derived deterministically from 2 extracted project(s). Most-advanced status: preclinical. Band: early_mechanism. Aging-relevance not LLM-reviewed in this pass.
Source: Deterministic